Merck KGaA (ETR:MRK)
Germany · Delayed Price · Currency is EUR | Market Cap | 51.02B -6.7% |
| Revenue (ttm) | 20.96B -1.7% |
| Net Income | 2.53B -10.2% |
| EPS | 5.83 -10.0% |
| Shares Out | 434.78M |
| PE Ratio | 20.14 |
| Forward PE | 14.62 |
| Dividend | 2.20 (1.82%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 334,857 |
| Average Volume | 370,347 |
| Open | 120.55 |
| Previous Close | 120.75 |
| Day's Range | 116.55 - 120.80 |
| 52-Week Range | 100.70 - 131.75 |
| Beta | 0.78 |
| RSI | 56.37 |
| Earnings Date | May 13, 2026 |
About Merck KGaA
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment also provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and test... [Read more]
Full Company ProfileFinancial Performance
In 2025, Merck KGaA's revenue was 21.10 billion, a decrease of -0.26% compared to the previous year's 21.16 billion. Earnings were 2.61 billion, a decrease of -6.09%.
Financial StatementsNews
Merck Foundation Mark World Hypertension Day 2026 by Providing Close to 1000 Scholarships for Future Cardiovascular Preventive, Cardiology, Diabetes, and Endocrinology Experts From 52 Countries
Business Wire IndiaMerck Foundation, the philanthropic arm of Merck KGaA Germany, marks ‘World Hypertension Day 2026’ together with First Ladies of Africa and Asia, and their partners Ministries of He...
Merck KGaA (MKGAF) Q1 2026 Earnings Call Highlights: Strong Start with Life Science and ...
Merck KGaA (MKGAF) Q1 2026 Earnings Call Highlights: Strong Start with Life Science and Electronics Leading Growth
Merck KGaA (MKGAF) Reports Strong Q1 Earnings with Record Harvest Volumes
Merck KGaA (MKGAF) Reports Strong Q1 Earnings with Record Harvest Volumes
Merck KGaA Earnings Call Transcript: Q1 2026
Solid organic growth in Life Science and Electronics offset Healthcare declines, with upgraded 2026 guidance reflecting strong Process Solutions and robust cash flow. One-off gains and disciplined cost management supported margins despite FX headwinds.
Merck KGaA Lifts FY26 Outlook, Backs Positive Mid-term View, Despite Weak Q1; Stock Gains
(RTTNews) - Shares of Merck KGaA were gaining around 8 percent in German trading after the science and technology major on Wednesday lifted its fiscal 2026 guidance and maintained mid-term view, despi...
Merck KGaA Raises 2026 Profit Guidance Amid Strong Demand
Merck KGaA Raises 2026 Profit Guidance Amid Strong Demand
Germany's Merck KGaA Raises Guidance
The outlook lift comes on expectations of stronger momentum in the group's life-sciences unit, resilience in healthcare, as well as its first-quarter performance and market conditions.
Merck KGaA Profit Drops In Q1
BRUSSELS (dpa-AFX) - Merck KGaA (MKKGY) revealed earnings for first quarter that Dropped, from the same period last yearThe company's bottom line totaled EUR659 million, or EUR1.52 per share. This...
Merck KGaA lifts earnings outlook on stronger Life Science momentum
Germany's Merck KGaA on Wednesday raised its 2026 adjusted operating profit guidance range, citing stronger momentum at its Life Science division and delayed competition for its Mavenclad multipl...
Reportable, Inc.: MilliporeSigma Builds On its Legacy As a Biotechnology Leader in Temecula
Temecula, California--(Newsfile Corp. - May 5, 2026) - Since first establishing operations in Temecula in 1989, MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, ...
MilliporeSigma Builds On its Legacy As a Biotechnology Leader in Temecula
Temecula, California--(Newsfile Corp. - May 5, 2026) - Since first establishing operations in Temecula in 1989, MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germ...
MilliporeSigma Receives 2026 Environment+Energy Leader Spotlight Award
NORTHAMPTON, MA / ACCESS Newswire / May 5, 2026 / The 2026 Environment+Energy Leader Awards have recognized MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germa...
Merck Foundation in Partnership With African First Ladies Announces the Winners of Their "More Than a Mother" and "Diabetes and Hypertension" Fashion, Film and Song Awards 2025
Business Wire IndiaMerck Foundation, the philanthropic arm of Merck KGaA Germany, in partnership with the Africa’s First Ladies, also the Ambassadors of “Merck Foundation more Than a Mother” announced...
EQS-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Merck KGaA Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 04....
Merck KgaA's New CEO Kai Beckmann Takes Charge As Belén Garijo Becomes Sanofi CEO
(RTTNews) - German science and technology major Merck KGaA's (MKGAY, MRK.DE) new Chief Executive Officer Kai Beckmann took charge on Friday, succeeding Belén Garijo, who joined French rival Sanofi SA ...
Merck Foundation With Kenya First Lady Celebrating Legacy to Transform Patient Care Landscape Nationwide in Kenya via More Than 328 Scholarships
Business Wire IndiaMerck Foundation, the philanthropic arm of Merck KGaA Germany, launched their Educating Linda Program to support girl education at Kenya State House, in partnership with H.E. Mrs. R...
Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT0...
Merck KGaA Transcript: AGM 2026
AGM 2026 highlighted strong financial growth, strategic investments in bioprocessing, rare diseases, and AI, and a leadership transition from Garijo to Beckmann. A stable EUR 2.2 dividend per share was proposed, with continued focus on resilience and innovation.
At Kenya State House, Merck Foundation in Partnership With Kenya First Lady and Ministry of Gender Launch Their "Educating Linda" Program to Support Girl Education
Business Wire IndiaMerck Foundation, the philanthropic arm of Merck KGaA Germany officially launched their Educating Linda program in Kenya in partnership with The First Lady of Kenya & Ambassador of…
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Merck KGaA Earnings Call Transcript: Q4 2025
Solid organic growth in Life Science and Healthcare offset macro and FX headwinds, with Electronics rebounding on AI-driven demand. 2026 guidance anticipates stable margins, mid-single-digit Life Science growth, and continued strength in Semiconductor Materials.
Merck KGaA Earnings Call Transcript: Q4 2025
2025 results met guidance despite FX and geopolitical headwinds, with stable sales and EBITDA growth. Life Science and Healthcare showed organic growth, while Electronics benefited from AI-driven demand. 2026 guidance reflects ongoing FX risks and MAVENCLAD U.S. exclusivity loss.
Germany's Merck KGaA Expects Currency Headwinds to Weigh on Earnings
The company anticipates currency headwinds would continue to weigh on its earnings this year, as the life-sciences and chemical company prepares for a leadership change.
Merck KGaA sees earnings decline of up to 4%
Germany's Merck KGaA said on Thursday it expects 2026 adjusted operating profit to slip by up to 4%, excluding currency effects.
Merck KGaA Transcript: 44th Annual J.P. Morgan Healthcare Conference
Positioned for growth in innovation-driven markets, the group focuses on Process Solutions, rare diseases, and Semiconductor Solutions, supported by disciplined M&A and a customer-centric reorganization. Midterm guidance targets mid-single digit organic growth, with margin expansion and robust pipeline development, especially in rare diseases.